KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Operating Leases (2019 - 2025)

Historic Operating Leases for CRISPR Therapeutics AG (CRSP) over the last 7 years, with Q4 2025 value amounting to $188.2 million.

  • CRISPR Therapeutics AG's Operating Leases fell 883.55% to $188.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $188.2 million, marking a year-over-year decrease of 883.55%. This contributed to the annual value of $188.2 million for FY2025, which is 883.55% down from last year.
  • CRISPR Therapeutics AG's Operating Leases amounted to $188.2 million in Q4 2025, which was down 883.55% from $192.8 million recorded in Q3 2025.
  • CRISPR Therapeutics AG's 5-year Operating Leases high stood at $234.2 million for Q2 2022, and its period low was $49.4 million during Q1 2021.
  • In the last 5 years, CRISPR Therapeutics AG's Operating Leases had a median value of $213.9 million in 2021 and averaged $204.4 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Operating Leases surged by 39969.92% in 2021 and then crashed by 883.55% in 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Operating Leases (Quarter) stood at $212.9 million in 2021, then rose by 7.19% to $228.2 million in 2022, then decreased by 2.27% to $223.0 million in 2023, then dropped by 7.44% to $206.4 million in 2024, then decreased by 8.84% to $188.2 million in 2025.
  • Its last three reported values are $188.2 million in Q4 2025, $192.8 million for Q3 2025, and $197.4 million during Q2 2025.